Marketing and commercialization for nRichDX and the Revolution Sample Prep System™. Purpose-built for liquid biopsy applications, the IVD-labeled Revolution System and innovative nRicher Cartridge™ provide higher yields and earlier detection of rare analytes, like cfDNA and cfRNA, from blood or urine specimens.

I enjoy helping start-up life sciences companies develop unique products and brands and implementing the commercial tactics that help them rapidly grow. I have years of life sciences and diagnostics marketing and commercial experience with both start-ups and industry leaders. Early-stage companies and pilot projects require experienced strategic understanding and the ability to execute tactically, often with very limited resources. Most start-ups have many ideas but limited resources for execution; therefore, experienced discernment and hands-on implementation are essential for success. I have experience with multiple start-ups and a practical understanding of the stages and timing for raising company and product awareness and successful commercialization.

Recruited into Marketing Leadership of this start-up on a fast growth trajectory.RoosterBio supplies cells, media systems, bioprocesses, and development services for the growth and expansion of mesenchymal stem/stromal cells (MSCs). The company's products resolve a critical supply bottleneck by enabling developers of MSC-derived therapies to grow large, therapeutic quantities of MSCs faster and more economically than other systems. My challenge was to elevate awareness of RoosterBio's unique products to target audiences, while building an effective marketing team and supporting the development of new products and commercialization efforts. • Built a highly effective marketing team with "immediate impact" on marketing performance. • Grew brand awareness from est. 2% - 3% to more than 20% through integrated marketing of social media, event/conference marketing, and inbound marketing content generation. • Designed and implemented a tailored, scalable phase-gate product development and launch process ("CDL") enabling a faster cadence of new product launches with improved leadership oversight. • Sourced and deployed collaboratively with Sales colleagues a better-fit CRM and Marketing Automation solution within first 3 months of tenure, saving an estimated $270k and speeding-up deployment and operational use by several months.

Lifespan offered parents complete DNA sequencing of their newborn children using a "freemium" business model. Lifespan provided information products from the genome to the child's parents and doctors when it was wanted by parents, or medically necessary by clinicians to reduce the time to diagnosis and improve patient quality of life. Among my challenges were to conceptualize the business model and make the business case to attract the resources required. Representative accomplishments included: • Attracted a team of experienced co-founders and advisors. • Successfully negotiated a unique, multi-million dollar deal with a Next-Generation Sequencing (NGS) category leader. • Created a best-of-class financial model and concise investment pitch deck in a technically challenging subject area and pitched to prospective investors and partners including C-Suite executives, HNW individuals, private equity/venture capital, payors, and hospital leadership. • Sourced and implemented a secure genome data warehouse, and bioinformatics analysis pipeline to house and process individual genome data. • Created Minimum Viable Product (MVP), attractive marketing and sales collateral, website, and social media presence and neonatal/pediatric sample collection kit.

Sonic Healthcare USA at the time was the $800M U.S. Division of Sonic Healthcare, headquartered in Sydney, Australia. Sonic Healthcare USA was an organization of 6,100 employees with the distinction of being the third-largest commercial diagnostic laboratory system in the U.S. The operation distinguished itself from other national labs by keeping a local market focus and identity across a federation of 14 lab brands united under the Sonic Healthcare USA name in 8 U.S. regions.My marketing programs and initiatives included a mix of inbound and outbound marketing to drive demand generation (Demand Gen) and ranged from sales collateral to billboards; from radio to television; and from business development to online strategy. This strategy included both consumer and Health Care Practitioner (HCP) and decision-maker targeting and business development. We made ourselves seen by SEO / Google; through website portal ads; social media engagement; and association and conference-specific website banner ads - to name a few tactics.• Established and led Sonic Healthcare USA's first national and corporate marketing group implementing brand consistency, sales enablement and demand lead generation tactics across all the Sonic Healthcare USA federation.• Secured support and led marketing efforts for the launch of Sonic Reference Laboratory as theorganization's molecular diagnostics (Mol Path / MDx) commercialization expert with the 2014 launch of Sonic's new state-of-the-art laboratory featuring clinical next-generation sequencing (NGS) capabilities.• Implemented secure, mobile (SaaS) sales enablement platform putting electronic versions of all sales support collateral and secure online communications for 300+ marketing and sales staff.• Created and led implementation of Direct-to-Consumer (DTC) strategy increasing customer satisfaction.

CBLPath joined the Sonic Healthcare federation of laboratories in November 2010. CBLPath was an $85M lab operation at the time. The CBLPath lab brand is still in existence within the Sonic Healthcare USA organization.In this role, I was concurrently responsible for three major initiatives. The expansion from a super-regional to a national laboratory presence (new geography), the initiation of molecular diagnostics to the test menu (new tests, such as the ThyroSeq(r) thyroid genomic classifier test in partnership with UPMC) and the introduction of the Best Practice Partnership Program to community-based pathologists (new client type). The partnership program selected independent community-based pathologists under threat of failure due to competing hospitals and labs. We would partner with fitting practices, driving business to their door through sales and marketing efforts and enhanced services enabled by our own teams. This provided our partner with a position of enhanced market strength - one which could be leveraged to thrive or to be better positioned for lucrative sale. • Hired and led a first-class staff of product managers and marketing communications team. • Contracted and managed CBLPath's first Agency of Record (AOR). • Led molecular oncology diagnostics (Mol Path / MDx) marketing effort.

I was recruited into Qiagen by my former manager at Life Technologies (LTI) due to my unique sales and marketing talents and scientific background in the field. Qiagen was focused on expansion of its DNA and RNA extraction and analysis tools and especially its growing automation / instrumentation platforms in multiple life sciences markets. What started as a $300M global enterprise at inception of tenure stood at $900M when I left, with a $1B target in clear view.Position focused on Molecular Diagnostics, Applied Testing (Forensics and Human ID, Veterinary Diagnostics, Biosecurity and Biodefense). Lab Automation / Instrumentation was a major factor in the nature and scope of my role with the EZ1, QIASymphony, and other automation systems. I initiated and established Qiagen's custom products business, which subsequently was implemented throughout the global enterprise. To ensure quality, Qiagen was not fond of custom product solutions. I made a convincing case for customization, which was aided by the attractiveness of stateside firms' spending power. Working collaboratively with others, I led a team in making Qiagen custom product solutions a reality -- which ended up being a lucrative decision benefitting all parties involved. We took in $1M in unanticipated revenue within the first 9 months, and a total of over $10M during my tenure.I also developed the North American Applied Testing market to sustained double-digit growth as the fastest growing business unit within Qiagen and working collaboratively with Qiagen business development, led the Integration Management Team for the acquisition of Genaco Biomedical Products. This team was comprised of departmental directors (Operations, IT, et al.), split from each organization. I reported directly to Qiagen's Global Executive Team in this capacity.At Qiagen I was recognized with leadership awards for two years and was selected for the CEO's new global Management Campus Program.

In the early 2000's, Nanogen was a $35M pioneer in electronic microarrays for life science applications, including diagnostics. In 2004, they merged with Epoch Biosciences. Here, I championed the commercial drive into molecular diagnostics (Mol Path / MDx) and was promoted from Product Manager to Associate Director during my tenure. I led a team of Product Marketing Managers and created a lauded program for Key Opinion Leader engagement, "Destination Diagnostics," resulting in the launch of five research protocols in 2001 and the first Analyte Specific Reagents (ASR) in 2002, with tactical launch plans for six new ASRs in a one year period.

Life Technologies; enzymes and automation in the Industrial BioProducts (IBP) segment. Life Technologies was acquired and today is a division within Thermo Fisher Scientific.

Recruited by OriGene Founder and previously laboratory colleague at HGS. OriGene focuses on tools for genetic / genomic and life-sciences applications at scale.

Amersham Pharmacia was acquired and today is part of GE Healthcare.

Successful pioneer in genomic discovery and translation to clinical applications. HGS was acquired and today is part of GlaxoSmithKline.